Clinical Trials Logo

Intracerebral Hemorrhage clinical trials

View clinical trials related to Intracerebral Hemorrhage.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04890379 Withdrawn - Clinical trials for Intracerebral Hemorrhage

Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in alleviating PHE and neurologic deficits in patients with ICH.

NCT ID: NCT04143113 Withdrawn - Ischemic Stroke Clinical Trials

Decision Aid Feasibility Trial for Families of Critically Ill Stroke Patients

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Severe strokes, including large artery acute ischemic stroke and intracerebral hemorrhage, continue to be the leading cause of death and disability in adults in the U.S. Due to concerns for a poor long-term quality of life, withdrawal of mechanical ventilation and supportive medical care with transition to comfort care is the most common cause of death in severe strokes, but occurs at a highly variable rate. Decision aids (DAs) are shared decision-making tools which have been successfully implemented and validated for many other diseases to assist difficult decision making. The investigators have developed a pilot DA for goals-of-care decisions for surrogates of severe, critically ill stroke patients. This was developed through qualitative research using semi-structured interviews in surrogate decision makers of traumatic brain injury patients and physicians, and adapted to severe strokes. The investigators now propose to pilot-test a DA for surrogates of critically ill severe stroke patients in a feasibility trial.

NCT ID: NCT02639819 Withdrawn - Clinical trials for Intracerebral Hemorrhage

Management of Intracerebral Hemorrhage With Aminocaproic Acid - Pilot Study

MANICHAN-PILOT
Start date: June 2016
Phase: Phase 1
Study type: Interventional

This is single-arm, open-label, safety and feasibility pilot study of ɛ-aminocaproic acid in ICH patients. Consecutive ICH volume with hematoma volume less than 30 mL by ABC/2 method presenting within 3 hours of symptom onset, meeting all inclusion criteria, and without exclusions will be consented and enrolled. Subjects will receive 5 grams of intravenous ɛ-aminocaproic acid over 1 hour, followed by the same at 1 mg/hour for 23 hours. Comupted tomography (CT) head will be done at 24 hours in order to follow hematoma size. Electrocardiogram, lower extremity venous Doppler and NIHSS will also be done at 24 hours. The patient will be followed in the clinic 30-90 days post discharge for functional status.

NCT ID: NCT01920763 Withdrawn - Clinical trials for Intracerebral Hemorrhage

Observational Study of Safety and Outcomes After Minimally Invasive Surgery for Intracerebral Hemorrhage

MiSPACE
Start date: July 2013
Phase: N/A
Study type: Observational

This pilot study will examine the safety and the clinical outcomes after minimally invasive surgery (using a parafascicular technique guided by diffusion-tensor imaging) for intracerebral hemorrhage in patients selected according to evidence-based criteria. The investigators will compare 30 day and 90 day outcomes of patients who have surgery to that predicted by previously reported models for recovery after ICH, and will also describe any surgical complications related to the procedure. The investigators hypothesize that this technique will have the same mortality rate and function outcome, if not better, when compared to the outcomes predicted by previous models.

NCT ID: NCT01730001 Withdrawn - Trauma Clinical Trials

Early Versus Late Intubation Trial in Physician Manned Emergency Medical Services

ELITE
Start date: January 1, 2015
Phase: N/A
Study type: Interventional

This study looks at advanced airway management in critically ill or injured patients treated by physician manned emergency medical services, comparing early (on-scene) intubation to late (emergency department) intubation.

NCT ID: NCT01498705 Withdrawn - Clinical trials for Intracerebral Hemorrhage

The Natural History of Procalcitonin in Hemorrhagic Stroke

Start date: December 2011
Phase: N/A
Study type: Observational

Approximately 12% of strokes in the United States are hemorrhagic.1 Hemorrhagic stroke can lead to multiple complications including fever that is not infectious. Identifying the cause of fever can help physicians choose the best care for the patient to try and prevent further damage to the already injured brain. Bacterial infection is one possible cause of fever in the stroke patient; however an incorrect diagnosis of infection can lead to unnecessary antibiotic use. Better screening tools for infection are being developed to help fight the problem of antibiotic resistance and unnecessary antibiotic use. Unnecessary use of antibiotics in patients increases the risk of adverse events and overall healthcare costs. Procalcitonin (PCT) is one such screening tool which has been used previously to help tell apart bacterial and nonbacterial causes of infection in other disease states; however, PCT has not been studied in hemorrhagic stroke patients. The purpose of this study is to understand the progress of PCT in hemorrhagic stroke patients in order to see whether PCT can be a useful marker for infection in these patients.